TRVI - Trevi has a new development chief

Trevi Therapeutics (TRVI) appointed 30-years industry veteran William Forbes, Pharm.D., as Chief Development Officer who will be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications."Bill's extensive experience in pharmaceutical product development will be extremely valuable as we complete enrollment and report top-line data from our Phase 2b/3 trial for chronic pruritus in patients with prurigo nodularis and our Phase 2 trial for chronic cough in patients with IPF and prepare for the next steps in development for both of these programs," president & CEO Jennifer L. Good commented.Most recently, he served as Founder, President and CEO of Vivelix Pharmaceuticals.SA Contributor Healthcare on the Move recently wrote, "Trevi Therapeutics: A Promising Pruritus Player In 2020"

For further details see:

Trevi has a new development chief